Felbamate for partial seizures: Results of a controlled clinical trial

I. E. Leppik, F. E. Dreifuss, G. W. Pledger, N. M. Graves, N. Santilli, I. Drury, J. Y. Tsay, M. P. Jacobs, E. Bertram, James Cereghino, G. Cooper, J. T. Sahlroot, P. Sheridan, M. Ashworth, S. I. Lee, T. L. Sierzant

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Felbamate (2–phenyl–1,3–propanediol dicarbamate) has a favorable preclinical profile in animal models of epilepsy. We present the results of a double–blind, randomized, placebo–controlled clinical trial in patients with partial seizures. Criteria for entry included a requirement for four or more partial seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine. Fifty–six patients (mean age, 31.4 years; 32 men, 24 women) completed the trial. The mean seizure frequencies for the 8–week periods analyzed were felbamate = 34.9, placebo = 40.2. Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction. The mean felbamate dosage was 2,300 mg/d. Plasma felbamate concentrations ranged from 18.4 to 51.9 mg/l, mean = 32.5 mg/l. Adverse experiences during felbamate therapy were minor and consisted primarily of nausea and CNS effects. This trial indicates that felbamate is safe and effective in the treatment of comedicated patients with severely refractory epilepsy.

Original languageEnglish (US)
Pages (from-to)1785-1789
Number of pages5
JournalNeurology
Volume41
Issue number11
StatePublished - 1991
Externally publishedYes

Fingerprint

felbamate
Controlled Clinical Trials
Seizures
Epilepsy
Placebos
Carbamazepine
Phenytoin
Controlled
Clinical Trials
Nausea

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Leppik, I. E., Dreifuss, F. E., Pledger, G. W., Graves, N. M., Santilli, N., Drury, I., ... Sierzant, T. L. (1991). Felbamate for partial seizures: Results of a controlled clinical trial. Neurology, 41(11), 1785-1789.

Felbamate for partial seizures : Results of a controlled clinical trial. / Leppik, I. E.; Dreifuss, F. E.; Pledger, G. W.; Graves, N. M.; Santilli, N.; Drury, I.; Tsay, J. Y.; Jacobs, M. P.; Bertram, E.; Cereghino, James; Cooper, G.; Sahlroot, J. T.; Sheridan, P.; Ashworth, M.; Lee, S. I.; Sierzant, T. L.

In: Neurology, Vol. 41, No. 11, 1991, p. 1785-1789.

Research output: Contribution to journalArticle

Leppik, IE, Dreifuss, FE, Pledger, GW, Graves, NM, Santilli, N, Drury, I, Tsay, JY, Jacobs, MP, Bertram, E, Cereghino, J, Cooper, G, Sahlroot, JT, Sheridan, P, Ashworth, M, Lee, SI & Sierzant, TL 1991, 'Felbamate for partial seizures: Results of a controlled clinical trial', Neurology, vol. 41, no. 11, pp. 1785-1789.
Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I et al. Felbamate for partial seizures: Results of a controlled clinical trial. Neurology. 1991;41(11):1785-1789.
Leppik, I. E. ; Dreifuss, F. E. ; Pledger, G. W. ; Graves, N. M. ; Santilli, N. ; Drury, I. ; Tsay, J. Y. ; Jacobs, M. P. ; Bertram, E. ; Cereghino, James ; Cooper, G. ; Sahlroot, J. T. ; Sheridan, P. ; Ashworth, M. ; Lee, S. I. ; Sierzant, T. L. / Felbamate for partial seizures : Results of a controlled clinical trial. In: Neurology. 1991 ; Vol. 41, No. 11. pp. 1785-1789.
@article{ea7bb88d8fa54515920d0cb7561d63bb,
title = "Felbamate for partial seizures: Results of a controlled clinical trial",
abstract = "Felbamate (2–phenyl–1,3–propanediol dicarbamate) has a favorable preclinical profile in animal models of epilepsy. We present the results of a double–blind, randomized, placebo–controlled clinical trial in patients with partial seizures. Criteria for entry included a requirement for four or more partial seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine. Fifty–six patients (mean age, 31.4 years; 32 men, 24 women) completed the trial. The mean seizure frequencies for the 8–week periods analyzed were felbamate = 34.9, placebo = 40.2. Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction. The mean felbamate dosage was 2,300 mg/d. Plasma felbamate concentrations ranged from 18.4 to 51.9 mg/l, mean = 32.5 mg/l. Adverse experiences during felbamate therapy were minor and consisted primarily of nausea and CNS effects. This trial indicates that felbamate is safe and effective in the treatment of comedicated patients with severely refractory epilepsy.",
author = "Leppik, {I. E.} and Dreifuss, {F. E.} and Pledger, {G. W.} and Graves, {N. M.} and N. Santilli and I. Drury and Tsay, {J. Y.} and Jacobs, {M. P.} and E. Bertram and James Cereghino and G. Cooper and Sahlroot, {J. T.} and P. Sheridan and M. Ashworth and Lee, {S. I.} and Sierzant, {T. L.}",
year = "1991",
language = "English (US)",
volume = "41",
pages = "1785--1789",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Felbamate for partial seizures

T2 - Results of a controlled clinical trial

AU - Leppik, I. E.

AU - Dreifuss, F. E.

AU - Pledger, G. W.

AU - Graves, N. M.

AU - Santilli, N.

AU - Drury, I.

AU - Tsay, J. Y.

AU - Jacobs, M. P.

AU - Bertram, E.

AU - Cereghino, James

AU - Cooper, G.

AU - Sahlroot, J. T.

AU - Sheridan, P.

AU - Ashworth, M.

AU - Lee, S. I.

AU - Sierzant, T. L.

PY - 1991

Y1 - 1991

N2 - Felbamate (2–phenyl–1,3–propanediol dicarbamate) has a favorable preclinical profile in animal models of epilepsy. We present the results of a double–blind, randomized, placebo–controlled clinical trial in patients with partial seizures. Criteria for entry included a requirement for four or more partial seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine. Fifty–six patients (mean age, 31.4 years; 32 men, 24 women) completed the trial. The mean seizure frequencies for the 8–week periods analyzed were felbamate = 34.9, placebo = 40.2. Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction. The mean felbamate dosage was 2,300 mg/d. Plasma felbamate concentrations ranged from 18.4 to 51.9 mg/l, mean = 32.5 mg/l. Adverse experiences during felbamate therapy were minor and consisted primarily of nausea and CNS effects. This trial indicates that felbamate is safe and effective in the treatment of comedicated patients with severely refractory epilepsy.

AB - Felbamate (2–phenyl–1,3–propanediol dicarbamate) has a favorable preclinical profile in animal models of epilepsy. We present the results of a double–blind, randomized, placebo–controlled clinical trial in patients with partial seizures. Criteria for entry included a requirement for four or more partial seizures per month despite concomitant therapeutic blood levels of phenytoin and carbamazepine. Fifty–six patients (mean age, 31.4 years; 32 men, 24 women) completed the trial. The mean seizure frequencies for the 8–week periods analyzed were felbamate = 34.9, placebo = 40.2. Felbamate was statistically superior to placebo in seizure reduction, percent seizure reduction, and truncated percent seizure reduction. The mean felbamate dosage was 2,300 mg/d. Plasma felbamate concentrations ranged from 18.4 to 51.9 mg/l, mean = 32.5 mg/l. Adverse experiences during felbamate therapy were minor and consisted primarily of nausea and CNS effects. This trial indicates that felbamate is safe and effective in the treatment of comedicated patients with severely refractory epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0025934106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025934106&partnerID=8YFLogxK

M3 - Article

C2 - 1944909

AN - SCOPUS:0025934106

VL - 41

SP - 1785

EP - 1789

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -